Could neoadjuvant chemotherapy increase postoperative complication risk of laparoscopic total gastrectomy? A mono-institutional propensity score-matched study in China

Table 2 Baseline characteristics of laparoscopic total gastrectomy after neoadjuvant chemotherapy group and laparoscopic total gastrectomy group after propensity-score matching

Clinical characteristic	NC-LTG group (n = 73)	LTG group (n = 73)	P value
Sex			0.843
Male	57	56
Female	16	17
Age (yr, mean ± SD)	59.56 ± 10.23	58.48 ± 12.35	0.565
BMI (kg/m2, mean ± SD)	23.16 ± 2.75	23.06 ± 3.91	0.860
History of abdominal surgery			1.000
Yes	14	14
No	59	59
ASA grade			0.646
I	6	2
II	61	67
III	6	4
Tumor diameter, cm (median, IQR)	4.5 (3.0-6.0)	4.0 (3.0-6.0)	0.716
pT			0.706
T0-T1	8	14
T2	12	9
T3	42	37
T4	11	13
pN			0.917
N0	26	32
N1	14	5
N2	16	16
N3	17	20
pTNM			0.710
0-I	14	17
II	25	23
III	34	33
Differentiation			0.619
Well/moderate	37	34
Poor/undifferentiated	36	39
Nerve invasion			0.730
Yes	25	27
No	48	46
Vascular invasion			0.210
Yes	26	19
No	47	54

NC-LTG: Laparoscopic total gastrectomy after neoadjuvant chemotherapy; LTG: Laparoscopic total gastrectomy; BMI: Body mass index; ASA: American Society of Anesthesiologists; IQR: Interquartile range; TNM: Tumor-node-metastasis.